MARKET

NLTX

NLTX

Neoleukin Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.90
-0.13
-0.89%
Closed 16:29 09/18 EDT
OPEN
14.18
PREV CLOSE
14.02
HIGH
14.32
LOW
13.62
VOLUME
429.23K
TURNOVER
--
52 WEEK HIGH
18.13
52 WEEK LOW
2.530
MARKET CAP
580.10M
P/E (TTM)
-4.8519
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Top Pharmaceutical Stocks for Q4 2020
These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2020.
Investopedia · 5d ago
Neoleukin Therapeutics Announces Appointment of Martin Babler to Board of Directors
SEATTLE, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointment of Martin Babler, President and Chief Executive Officer
GlobeNewswire · 09/10 13:00
Neoleukin Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference
SEATTLE, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at
GlobeNewswire · 09/09 13:00
What Type Of Shareholders Own The Most Number of Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) Shares?
The big shareholder groups in Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) have power over the company. Institutions...
Simply Wall St. · 08/20 18:26
Neoleukin (NLTX) Upgraded to Buy: What Does It Mean for the Stock?
Neoleukin (NLTX) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks · 08/19 17:00
Neoleukin Therapeutics (NLTX) Investor Presentation - Slideshow
The following slide deck was published by Neoleukin Therapeutics, Inc. in conjunction with this event.
Seekingalpha · 08/16 19:36
Neoleukin Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS results.
Benzinga · 08/13 17:31
Neoleukin Therapeutics EPS misses by $0.04
Neoleukin Therapeutics (NLTX): Q2 GAAP EPS of -$0.20 misses by $0.04.Cash and equivalents of $129.6MPress Release
Seekingalpha · 08/12 20:04
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NLTX stock price target is 22.33 with a high estimate of 30.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 93
Institutional Holdings: 25.30M
% Owned: 60.61%
Shares Outstanding: 41.75M
TypeInstitutionsShares
Increased
27
4.54M
New
40
-849.43K
Decreased
12
1.31M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.06%
Pharmaceuticals & Medical Research
+0.57%
Key Executives
Chairman/Independent Director
Todd Simpson
President/Chief Executive Officer/Director
Jonathan Drachman
Chief Financial Officer/Secretary
Robert Ho
Vice President
Leslie Aberman
Vice President
Samantha Willing
Director
Martin Babler
Director
Erin Lavelle
Independent Director
M. Cantey Boyd
Independent Director
Sarah Noonberg
Independent Director
Lewis Williams
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average NLTX stock price target is 22.33 with a high estimate of 30.00 and a low estimate of 20.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About NLTX
Neoleukin Therapeutics, Inc., formerly Aquinox Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is focused on the development and commercialization of computationally-designed protein therapeutics to address unmet medical needs in immuno-oncology, inflammation, and autoimmunity. Its computational platform allows it to design new de novo proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its lead program, NL-201, is a computationally-designed de novo protein therapeutic. NL-201 is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. NL-201 is designed for use as a single-agent or in combination with complementary therapeutic modalities.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Neoleukin Therapeutics Inc stock information, including NASDAQ:NLTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NLTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NLTX stock methods without spending real money on the virtual paper trading platform.